Table 2.

Key parameters in the agent-based model.

Parameter	%	Vaccine received (%)				Range		Reference
		LAIV	IIV-IM	IIV-ID	No.	Minimum	Maximum
Coverage by age, years
6–23 months	70.4	0.0	100.0	0.0		69.6	71.2	Adapted from [38,39]
2–4	68.1	52.0	48.0	0.0		67.3	68.9
5–8	61.0	52.0	48.0	0.0		60.2	61.8
9–17	52.9	52.0	48.0	0.0		52.1	53.7
18–49	32.3	2.0	97.0	1.0		31.9	32.7
50–64	45.3	0.0	99.0	1.0		44.9	45.7
65–106	65.0	0.0	100.0	0.0		64.6	65.4
LAIV contraindications by age, years
2–4	8.8							[40]
5–17	1.0
Absolute vaccine coverage increases with choice	6.5					3.25	11.25	[1]
Vaccine cost, US$
IIV-IM					10.69	0.00	21.38	[41]
LAIV					23.70	0.00	47.40
IIV-ID					15.69	0.00	31.38
Vaccine administration cost, US$					25.08			[28]
Increased cost of choice	5.0					2.5	7.5	[42]
Latent period, days^a					1.9	1	2	[17,20–25,43]
Infectious period, days^a					4.1	3	6
Asymptomatic rate^b	33.0
Asymptomatic reduction in infectivity^c	50.0
Symptomatic absenteeism^b	50.0
Vaccine effectiveness^b	59.0							[44]

IIV = inactivated influenza vaccine; LAIV = live attenuated influenza vaccine; IM = intramuscular; ID = intradermal.

Drawn from a truncated Weibull distribution with the listed nominal (mean), minimum and maximum values.

Probability point estimate that does not vary across simulations; within each simulation, it is the action potential threshold above which an outcome (i.e., exhibit symptoms, stay home from work, or vaccine protects against disease) occurs and below which it does not.

A constant that does not vary across simulations.